Barcelona-based Almirall reports 6.6% Q1 2024 sales growth, 18% increase in European dermatology business, and 10.7% R&D investment.
Almirall, a Barcelona-based global biopharmaceutical company, announced strong first-quarter 2024 sales growth of 6.6% overall, with 18% increase in European dermatology business, driven by biologics and broad product portfolio. Net sales reached €247.4M; EBITDA increased by 1.4% YoY to €52.5M, gross margin at 63.5%. The company continues to invest in Ebglyss launch and R&D efforts, allocating 10.7% of net sales.
May 13, 2024
3 Articles